Physician profile
Matthew Griffith
NPI 1609866714
$1,231.70
in general payments reported to CMS, 2019-2025
11 companies · $966 in 2025
The $966 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $64.39 · 2024: $201 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.00 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $333.31 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $254.54 | 2023-2025 | Zerbaxa, Pifeltro, Dificid |
| Aimmune Therapeutics, INC. | $132.51 | 2024-2025 | Vowst |
| Gilead Sciences, INC. | $122.70 | 2025 | Yeztugo |
| Viiv Healthcare Company | $115.86 | 2025 | Dovato |
| Insmed, INC. | $99.94 | 2024-2025 | Arikayce |
| Melinta Therapeutics, LLC | $69.95 | 2025 | Orbactiv, Rezzayo, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $39.46 | 2024-2025 | Nuzyra |
| Pfizer INC. | $26.95 | 2025 | |
| Shionogi INC | $19.91 | 2024 | Fetroja |
| Ferring Pharmaceuticals INC. | $16.57 | 2025 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.